SETTING: Recent studies suggest that the prevalence of drug-resistant tuberculosis (TB) in sub-Saharan Africa may be rising. This is of concern, as human immunodeficiency virus (HIV) co-infection in multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB has been associated with exceedingly high mortality rates. OBJECTIVE: To identify risk factors associated with mortality in MDR- and XDR-TB patients co-infected with HIV in South Africa. DESIGN: Case-control study of patients who died of all causes within 2 years of diagnosis with MDR- or XDR-TB. RESULTS: Among 123 MDR-TB patients, 78 (63%) died following diagnosis. CD4 count ≤ 50 (HR 4.64, P = 0.01) and 51-200 cells/mm(3) (HR 4.17, P = 0.008) were the strongest independent risk factors for mortality. Among 139 XDR-TB patients, 111 (80%) died. CD4 count ≤ 50 cells/mm(3) (HR 4.46, P = 0.01) and resistance to all six drugs tested (HR 2.54, P = 0.04) were the principal risk factors. Use of antiretroviral therapy (ART) was protective (HR 0.34, P = 0.009). CONCLUSIONS: Mortality due to MDR- and XDR-TB was associated with greater degree of immunosuppression and drug resistance. Efforts to reduce mortality must focus on preventing the amplification of resistance by strengthening TB treatment programs, as well as reducing the pool of immunosuppressed HIV-infected patients through aggressive HIV testing and ART initiation.
SETTING: Recent studies suggest that the prevalence of drug-resistant tuberculosis (TB) in sub-Saharan Africa may be rising. This is of concern, as human immunodeficiency virus (HIV) co-infection in multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB has been associated with exceedingly high mortality rates. OBJECTIVE: To identify risk factors associated with mortality in MDR- and XDR-TBpatients co-infected with HIV in South Africa. DESIGN: Case-control study of patients who died of all causes within 2 years of diagnosis with MDR- or XDR-TB. RESULTS: Among 123 MDR-TBpatients, 78 (63%) died following diagnosis. CD4 count ≤ 50 (HR 4.64, P = 0.01) and 51-200 cells/mm(3) (HR 4.17, P = 0.008) were the strongest independent risk factors for mortality. Among 139 XDR-TBpatients, 111 (80%) died. CD4 count ≤ 50 cells/mm(3) (HR 4.46, P = 0.01) and resistance to all six drugs tested (HR 2.54, P = 0.04) were the principal risk factors. Use of antiretroviral therapy (ART) was protective (HR 0.34, P = 0.009). CONCLUSIONS: Mortality due to MDR- and XDR-TB was associated with greater degree of immunosuppression and drug resistance. Efforts to reduce mortality must focus on preventing the amplification of resistance by strengthening TB treatment programs, as well as reducing the pool of immunosuppressed HIV-infectedpatients through aggressive HIV testing and ART initiation.
Authors: Timothy H Holtz; Maya Sternberg; Steve Kammerer; Kayla F Laserson; Vija Riekstina; Evija Zarovska; Vija Skripconoka; Charles D Wells; Vaira Leimane Journal: Ann Intern Med Date: 2006-05-02 Impact factor: 25.391
Authors: Stephen D Lawn; Francesca Little; Linda-Gail Bekker; Richard Kaplan; Elizabeth Campbel; Catherine Orrell; Robin Wood Journal: AIDS Date: 2009-01-28 Impact factor: 4.177
Authors: Charles D Wells; J Peter Cegielski; Lisa J Nelson; Kayla F Laserson; Timothy H Holtz; Alyssa Finlay; Kenneth G Castro; Karin Weyer Journal: J Infect Dis Date: 2007-08-15 Impact factor: 5.226
Authors: Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani Journal: Lancet Infect Dis Date: 2009-03 Impact factor: 25.071
Authors: G Sotgiu; G Ferrara; A Matteelli; M D Richardson; R Centis; S Ruesch-Gerdes; O Toungoussova; J-P Zellweger; A Spanevello; D Cirillo; C Lange; G B Migliori Journal: Eur Respir J Date: 2009-02-27 Impact factor: 16.671
Authors: Kathrin Zürcher; Marie Ballif; Lukas Fenner; Sonia Borrell; Peter M Keller; Joachim Gnokoro; Olivier Marcy; Marcel Yotebieng; Lameck Diero; E Jane Carter; Neesha Rockwood; Robert J Wilkinson; Helen Cox; Nicholas Ezati; Alash'le G Abimiku; Jimena Collantes; Anchalee Avihingsanon; Kamon Kawkitinarong; Miriam Reinhard; Rico Hömke; Robin Huebner; Sebastien Gagneux; Erik C Böttger; Matthias Egger Journal: Lancet Infect Dis Date: 2019-02-08 Impact factor: 25.071
Authors: Francesca Conradie; Andreas H Diacon; Nosipho Ngubane; Pauline Howell; Daniel Everitt; Angela M Crook; Carl M Mendel; Erica Egizi; Joanna Moreira; Juliano Timm; Timothy D McHugh; Genevieve H Wills; Anna Bateson; Robert Hunt; Christo Van Niekerk; Mengchun Li; Morounfolu Olugbosi; Melvin Spigelman Journal: N Engl J Med Date: 2020-03-05 Impact factor: 91.245
Authors: Lizanne de Kock; Sherwin K B Sy; Bernd Rosenkranz; Andreas H Diacon; Kim Prescott; Kenneth R Hernandez; Mingming Yu; Hartmut Derendorf; Peter R Donald Journal: Antimicrob Agents Chemother Date: 2014-08-11 Impact factor: 5.191
Authors: Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren Journal: Lancet Respir Med Date: 2014-03-24 Impact factor: 30.700
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405